150mg is an oval-shaped, yellow, film-coated tablet debossed with “TUC” on one side and “150” on the other. It contains tucatinib, a prescription kinase inhibitor used alongside other medications to treat advanced HER2-positive breast and colorectal cancers.
Physical & Composition Details
Shape and Color: Oval-shaped, yellow film-coated.
Markings: Debossed with "TUC" on one side and "150" on the reverse.
Active Ingredient: Tucatinib (150 mg per tablet).
Inactive Ingredients: Tablet core includes copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, microcrystalline cellulose, and magnesium stearate.
Uses & Administration
Indication: Used with trastuzumab and capecitabine for HER2-positive metastatic breast cancer (including cases spread to the brain) or certain unresectable/colorectal cancers.
Standard Dose: Two 150mg tablets (totaling 300 mg) taken orally twice daily.
Handling: Tablets must be swallowed whole; do not chew, crush, or split.
Common Side Effects
Severe or mild diarrhea
Hand-foot syndrome (rash, redness, or pain on palms and soles)
Nausea, vomiting, and mouth sores
Elevated liver enzymes/liver problems
Fatigue and decreased appetite
If you'd like, I can provide details on:
Storage instructions for the medication
Managing side effects like diarrhea or nausea
Drug interactions to avoid while taking tucatinib
This product requires a prescription to be purchased.
150mg is an oval-shaped, yellow, film-coated tablet debossed with “TUC” on one side and “150” on the other. It contains tucatinib, a prescription kinase inhibitor used alongside other medications to treat advanced HER2-positive breast and colorectal cancers.
Physical & Composition Details
Shape and Color: Oval-shaped, yellow film-coated.
Markings: Debossed with "TUC" on one side and "150" on the reverse.
Active Ingredient: Tucatinib (150 mg per tablet).
Inactive Ingredients: Tablet core includes copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, microcrystalline cellulose, and magnesium stearate.
Uses & Administration
Indication: Used with trastuzumab and capecitabine for HER2-positive metastatic breast cancer (including cases spread to the brain) or certain unresectable/colorectal cancers.
Standard Dose: Two 150mg tablets (totaling 300 mg) taken orally twice daily.
Handling: Tablets must be swallowed whole; do not chew, crush, or split.
Common Side Effects
Severe or mild diarrhea
Hand-foot syndrome (rash, redness, or pain on palms and soles)
Nausea, vomiting, and mouth sores
Elevated liver enzymes/liver problems
Fatigue and decreased appetite
If you'd like, I can provide details on:
Storage instructions for the medication
Managing side effects like diarrhea or nausea
Drug interactions to avoid while taking tucatinib
This product requires a prescription to be purchased.
